Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

去年，RSV疫苗技惊四座；今年，却迅速回落。日前，葛兰素史克发布财报，其RSV疫苗Arexvy第三季度销售额同比下降74%，销售额为1.88亿英镑，折合2.4亿美元。 最核心的，是美国疾病控制与预防中心（CDC）的免疫接种建议范围缩小。此前，RSV疫苗被建议用于60岁以上的老年人接种。而在今年6月份，美国CDC调整了接种人群的建议。调整之后，范围大幅缩小，局限于： ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

全球首家公布RSV候选疫苗与已获批重磅RSV疫苗头对头临床试验结果、且结果积极的厂家，来自中国。当开年至今无一款国产创新型疫苗获批上市，二类疫苗又几乎迎来全员内卷、“价格战”四处打响时，中国创新疫苗行业终于传来了一则好消息：一款国产呼吸道合胞病毒（R ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

当前正是第三季度财报季，中国疫苗行业在当前经济周期波动下业绩承压，以往热卖的疫苗大品种也在面临国内市场进一步降价竞争的挑战。作为生物医药细分赛道的国产创新疫苗行业，如何寻找到一条破局企稳，拨云见日的路径，是决定各国产疫苗厂家未来商业生死的核心战略考量 ...